TL;DR Yes, blood type appears to change how quickly nattokinase dissolves a blood clot, at least in the laboratory. A February 2026 study in Scientific Reports tested nattokinase against blood samples from all eight ABO/Rh blood types and found real, statistically significant differences in clot dissolution time, with type O blood clearing clots fastest and AB-negative blood clearing them slowest. Age mattered even more than blood type. What the study did not test is oral dosing. Researchers used one fixed concentration in test tubes, not different capsule doses in real people, so this is a mechanistic clue about how nattokinase and blood interact, not a personalized dosing chart.
What Is Nattokinase, and Why Do People Use It?
Nattokinase is an enzyme derrived from natto, a fermented soybean dish that has been part of Japanese cuisine for centuries. People take it because it has a specific, well-documented job: breaking down fibrin, the protein mesh that gives a blood clot its structure. When fibrin builds up excessively, it can stiffen blood vessels and slow circulation. Nattokinase’s fibrinolytic activity is why it has become a go-to option for people focused on healthy blood flow, vascular flexibility, and general cardiovascular resilience as they age.
Until recently, most nattokinase content, ours included, talked about dosing in fairly generic terms. The new research changes that conversation, even if it does not yet finish it.
The Clot Dissolution Study, in Plain Terms
Researchers at Marwadi University in India collected blood from 1,796 people covering every combination of ABO and Rh blood type, then ran a controlled experiment. They let the blood clot in test tubes, added a fixed concentration of nattokinase, and timed exactly how long each clot took to fully dissolve. They repeated the core findings in a second, independent group of 562 samples from nine cities, and the results held up closely across locations.
The pattern was consistent. Type O blood dissolved clots fastest, on average. Type AB blood dissolved them slowest. The single fastest result belonged to a young adult with O-positive blood, at about 25 minutes. The single slowest belonged to an AB-negative woman between 66 and 70, at about 44 minutes, a gap of roughly 19 minutes between the two ends of the spectrum.
“NK-mediated CDT is not uniform across blood groups and is influenced by age and blood group antigen composition.”
That line, from the study’s own conclusion, is the honest summary. Clot dissolution time (CDT) is not one-size-fits-all. But it is worth sitting with what this actually measured: a lab test tube reaction over a fixed window, not a person’s lived experience of taking a capsule with breakfast.
Why Blood Type Seems to Matter
The leading explanation involves von Willebrand factor (vWF), a protein that helps stabilize clots. Prior research has established that people with non-O blood types tend to carry meaningfully higher levels of vWF than people with type O blood. A denser, more reinforced clot is logically harder and slower for any fibrinolytic enzyme, nattokinase included, to break down. This new study’s electron microscope images support that idea visually: red blood cells in type O samples returned to their normal, healthy shape well before red blood cells in AB-negative samples did.
The researchers also ran computer-based molecular modeling to look at how nattokinase interacts with the Rh protein specifically. Their models suggested Rh-positive blood may bind more efficiently with the enzyme than Rh-negative blood does. This is a genuinely interesting mechanistic hypothesis, but it is a modeling result, not a confirmed biological pathway, and the authors are clear that it needs direct laboratory validation before anyone treats it as settled.
Age Mattered More Than Blood Type
Here is the part that gets buried in a lot of the coverage: when researchers ran their statistical analysis, age had the strongest individual effect on clot dissolution time of any factor they measured, ahead of blood type and ahead of Rh status. The relationship was not a straight line, either. Clot dissolution was fastest in the 31 to 35 age range, slower in both younger participants and, more sharply, in older ones. By the 66 to 70 age bracket, dissolution time was meaningfully longer than the mid-30s baseline.
The slowest single result in the entire study belonged to a specific combination: women, AB-negative blood, and the 66 to 70 age group. That is a real, data-backed finding, and it lines up with decades of separate research showing that fibrinolytic capacity naturally declines with age as inhibitor proteins increase and clot-clearing enzymes decline.
Nattokinase Response Hierarchy by Blood Type
Blood Type | vWF Level | Mesh Characteristics | Dissolution Speed | Clinical Action/Dosing Strategy |
|---|---|---|---|---|
Type O | Lowest | Least resistant mesh | Fastest (O+ is peak) | Standard 2,000 FU Baseline |
Type B | Intermediate | Moderate density | Intermediate | Standard Baseline; Monitor |
Type A | High | Denser mesh | Slow/Resistant | Titration Required; Close Monitoring |
Type AB | Highest | Most resistant mesh | Slowest (AB- is lowest) | Aggressive Titration & Oversight |
What This Doesn’t Tell Us Yet
This is the section worth reading twice. The study used one nattokinase concentration across every sample. It did not test 2,000 FU against 4,000 FU against 8,000 FU. It did not follow anyone taking a daily capsule over weeks or months. It measured how fast an enzyme dissolved a static clot in a tube, which is a meaningful signal about biological mechanism, not a validated dosing protocol.
The researchers say so themselves, recommending “large-scale in vivo validation studies to optimize NK dosing” as the necessary next step. In vivo means in a living body. This study was not that. Anyone telling you your blood type determines your exact FU dose is extrapolating well past what the current evidence supports.
What the study does support is a reasonable, hedged takeaway: individual biology likely plays some role in how efficiently nattokinase does its job, blood type and age chief among the variables identified so far, and that is worth discussing with a healthcare provider who knows your full picture, particularly if you are older, have a non-O blood type, or take blood thinners.
Nattokinase 4000FU Ingredient Overview
AgeImmune’s Nattokinase 4000FU supplement is standardized so every capsule delivers a measured, consistent level of enzymatic activity, sourced from Japan and formulated without magnesium stearate, silica, or silicon dioxide.
Sourcing matters here too. Nattokinase originates from natto, a fermented soybean dish with centuries of history in Japan, and AgeImmune’s raw enzyme is imported directly from Japan rather than produced through a domestic substitute process. That keeps the supply chain close to where the enzyme has the longest track record of production and use, supporting consistency from batch to batch.
Nattokinase is often described as part of a broader cardiovascular stack, and that pairing isn’t arbitrary. The combination with Brilliant D3 Complex makes sense because each ingredient targets a different part of vascular health rather than duplicating nattokinase’s job. Nattokinase’s role is specifically clot-related, breaking down fibrin, while vitamin K2 works on a separate front, helping direct calcium toward bone rather than allowing it to accumulate in arterial walls, and vitamin D3 supports the pathways that make K2’s calcium-regulating activity possible in the first place. Magnesium contributes by supporting healthy vascular tone and smooth muscle relaxation, and omega-3s are more associated with healthy triglyceride levels and reducing inflammatory load on blood vessels.
Together, the combination addresses clot activity, arterial calcification, vessel tone, and inflammation as separate but related pieces of cardiovascular function, rather than one ingredient trying to cover all four.
Safety and What to Watch For
Nattokinase is a genuinely active enzyme, and that is exactly why it deserves respect, not casual use. If you already take aspirin, warfarin, or another prescription blood thinner, combining that with nattokinase can meaningfully raise bleeding risk. The same caution applies before surgery, during pregnancy or breastfeeding, or if you have an existing bleeding disorder. None of that changes based on your blood type. It applies to everyone, and it is exactly the kind of decision worth making with your doctor rather than a blog post.
Key Takeaways
- A 2026 Scientific Reports study found real, statistically significant differences in how fast nattokinase dissolved blood clots across different ABO and Rh blood types, in a laboratory setting.
- Type O blood cleared clots fastest on average; type AB-negative blood cleared them slowest, with roughly a 19-minute gap between the fastest and slowest individual results.
- Age had the single strongest effect on clot dissolution time, with the 66 to 70 age bracket showing meaningfully slower results than the 31 to 35 age bracket.
- The study did not test different nattokinase doses and does not establish a validated blood-type-specific dosing protocol. Its own authors call for further in vivo research.
- If you take blood thinners, are pregnant or breastfeeding, or have a bleeding disorder, talk to your healthcare provider before starting nattokinase, regardless of blood type.
Frequently Asked Questions
Does blood type affect how nattokinase works?
Laboratory research published in Scientific Reports in 2026 found that nattokinase dissolved blood clots at different speeds depending on ABO and Rh blood type, with type O blood dissolving clots fastest and AB-negative blood dissolving them slowest. This was measured in test tubes, not in people taking oral nattokinase, so it points to a biological mechanism worth further study rather than a confirmed dosing rule.
Should I take a different nattokinase dose based on my blood type?
Not based on current evidence. The 2026 study used a single, fixed concentration of nattokinase across all blood types and did not test dose variations. There is currently no validated, dose-specific protocol tied to blood type. A standard starting point, such as AgeImmune’s 4,000 FU capsule, remains the reasonable baseline, adjusted only under the guidance of a healthcare provider.
Does age affect nattokinase’s effectiveness?
Yes, more than blood type did in this particular study. Clot dissolution time was fastest around ages 31 to 35 and slower in both younger and, especially, older age groups, consistent with the well-established pattern of declining fibrinolytic activity as people age.
Is nattokinase safe to take with blood thinners?
Combining nattokinase with prescription blood thinners or antiplatelet medications like aspirin can increase bleeding risk and should only be done under medical supervision. This applies regardless of blood type.
What is fibrinolytic activity, and why does it matter for nattokinase?
Fibrinolytic activity refers to an enzyme’s ability to break down fibrin, the protein mesh that forms the structural backbone of a blood clot. It is measured in Fibrinolytic Units (FU) rather than milligrams, because FU reflects actual enzymatic activity, which is what determines how effectively the enzyme works.
Related Reading
- Nattokinase Benefits Explained: Why a Traditional Japanese Food Still Matters for Modern Circulation
- What Are the Benefits of Nattokinase? A Functional Medicine Deep Dive
- Cardiovascular Disease: America’s #1 Killer
The Bottom Line
The one-size-fits-all era of supplementation probably is fading, and this study is a genuinely useful early data point in that direction. But there is a real difference between “your biology likely influences how this enzyme performs” and “here is your personalized dose.” The first is where the science currently stands. The second is still years of research away. If you are curious where you fall on the clot-dissolution spectrum this study describes, the more useful next step is not guessing at a dose, it is asking your provider whether your blood type, age, and full health picture change anything about how you approach circulatory support, and choosing a clean, standardized nattokinase formula in the meantime.
References
- Bhatt, T.C. & Bishoyi, A.K. “Discovery of age and blood group associated variability in nattokinase mediated thrombolysis and its relevance to cardiovascular management.” Scientific Reports 16, 7690 (2026). https://www.nature.com/articles/s41598-026-38130-5
- Ward, S.E., O’Sullivan, J.M. & O’Donnell, J.S. “The relationship between ABO blood group, von Willebrand factor, and primary hemostasis.” Blood 136, 2864-2874 (2020). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751360
- Jensen, G.S., Lenninger, M., Ero, M.P. & Benson, K.F. “Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker.” Integrated Blood Pressure Control 9, 95-104 (2016). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066864
- Vasan, S.K. et al. “ABO blood group and risk of thromboembolic and arterial disease.” Circulation 133, 1449-1457 (2016). https://pubmed.ncbi.nlm.nih.gov/26939588
DISCLAIMER:
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Please consult your doctor before starting any supplement program, especially if you take blood thinners, are pregnant or breastfeeding, or have a medical condition.
